Nanion Corporate Blog


07.03.2018: Attend our Symposium at SOT Annual Meeting

Title: "Cytotoxicity Assessments for Cancer Prevention and Optogenetics: the Future of Toxicology?"

This collaborative session with Ncardia presents an assay methodology for in vitro investigations of adjuvant chemotherapy related to tumor recurrence prevention. 
We will discuss cardiotoxicity investigations of iPS-derived cells using optogenetic stimulation. State of the art transfection and optogenetic technology allow simultaneous recordings of voltage and contractility, for efficient risk evaluation.

Monday March 12, 2018
3:00 PM – 4:00 PM
Convention Center 217A / Room 217A

Do not miss these oral presentations:

  • Elena Dragicevic, Nanion Technologies
    Title: "Innovations for cell monitoring in safety and toxicity assays."
  • Greg Luerman, Ncardia
    Title: "Optogenetic control of transiently transfected hiPSC-derived cardiomyocytes for the assessment of drug related cardiotoxicity."

Register here to reserve your spot.

Back to Overview

Contact Us

Please type your full name.
Invalid email address.
Invalid Input
Invalid Input
Nanion Technologies GmbH

Ganghoferstr. 70A
D-80339 Munich - Germany